These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26648749)

  • 41. Different Profile of Efficacy of Thiopurines in Ulcerative Colitis and Crohn's Disease.
    Rispo A; Testa A; De Palma GD; Donetto S; Diaferia M; Musto D; Nardone O; Maione F; Caporaso N; Castiglione F
    Inflamm Bowel Dis; 2015 Nov; 21(11):2570-5. PubMed ID: 26222340
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Positioning Therapy for Ulcerative Colitis.
    Grinspan A; Kornbluth A
    Curr Gastroenterol Rep; 2015 Aug; 17(8):29. PubMed ID: 26143627
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Review article: strategies for the management of chronic unremitting ulcerative colitis.
    Mehta SJ; Silver AR; Lindsay JO
    Aliment Pharmacol Ther; 2013 Jul; 38(2):77-97. PubMed ID: 23718288
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.
    Bressler B; Marshall JK; Bernstein CN; Bitton A; Jones J; Leontiadis GI; Panaccione R; Steinhart AH; Tse F; Feagan B;
    Gastroenterology; 2015 May; 148(5):1035-1058.e3. PubMed ID: 25747596
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.
    Lopez A; Ford AC; Colombel JF; Reinisch W; Sandborn WJ; Peyrin-Biroulet L
    Dig Liver Dis; 2015 May; 47(5):356-64. PubMed ID: 25661014
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.
    Favale A; Onali S; Caprioli F; Pugliese D; Armuzzi A; Macaluso FS; Orlando A; Viola A; Fries W; Rispo A; Castiglione F; Mocci G; Chicco F; Usai P; Calabrese E; Biancone L; Monteleone G; Fantini MC;
    Inflamm Bowel Dis; 2019 Oct; 25(11):1805-1812. PubMed ID: 30931477
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model.
    Scott FI; Shah Y; Lasch K; Luo M; Lewis JD
    Inflamm Bowel Dis; 2018 Jan; 24(2):286-295. PubMed ID: 29361100
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biologics in inflammatory bowel disease: what are the data?
    Côté-Daigneault J; Bouin M; Lahaie R; Colombel JF; Poitras P
    United European Gastroenterol J; 2015 Oct; 3(5):419-28. PubMed ID: 26535119
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice].
    Shapina MV; Nanaeva BA
    Ter Arkh; 2020 Apr; 92(2):67-73. PubMed ID: 32598721
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current new challenges in the management of ulcerative colitis.
    Fukuda T; Naganuma M; Kanai T
    Intest Res; 2019 Jan; 17(1):36-44. PubMed ID: 30678445
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Induction and maintenance infliximab therapy in children with moderate to severe ulcerative colitis: Retrospective, multicenter study.
    Iwańczak BM; Kierkuś J; Ryżko J; Szczepanik M; Więcek S; Czaja-Bulsa G; Kacperska M; Korczowski B; Maślana J; Iwańczak F
    Adv Clin Exp Med; 2017; 26(1):57-61. PubMed ID: 28397433
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Medical therapy of inflammatory bowel diseases: ulcerative colitis].
    Lakatos L; Lakatos PL
    Orv Hetil; 2007 Jun; 148(25):1163-70. PubMed ID: 17573252
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inflammatory bowel disease: current therapeutic options.
    Domènech E
    Digestion; 2006; 73 Suppl 1():67-76. PubMed ID: 16498254
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Infliximab and ulcerative colitis.
    Cottone M; Mocciaro F; Modesto I
    Expert Opin Biol Ther; 2006 Apr; 6(4):401-8. PubMed ID: 16548766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis.
    Yokomizo L; Limketkai B; Park KT
    BMJ Open Gastroenterol; 2016; 3(1):e000093. PubMed ID: 27195130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study].
    Rutka M; Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Molnár T
    Orv Hetil; 2016 May; 157(18):706-11. PubMed ID: 27106726
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comprehensive review and update on ulcerative colitis
    Gajendran M; Loganathan P; Jimenez G; Catinella AP; Ng N; Umapathy C; Ziade N; Hashash JG
    Dis Mon; 2019 Dec; 65(12):100851. PubMed ID: 30837080
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists.
    Fausel R; Afzali A
    Ther Clin Risk Manag; 2015; 11():63-73. PubMed ID: 25609972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.